CoChat
Sign Up
Cited by 196

The DOI matches its Crossref record.

CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Patten, Piers E. M., Buggins, Andrea G. S., Richards, Julie, Wotherspoon, Andrew, Salisbury, Jon, Mufti, Ghulam J., Hamblin, Terry J., Devereux, Stephen·2008·Blood
DOI 10.1182/blood-2007-08-108605
Open this paper in CoChat — free account

Abstract

Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with a highly variable outcome. The prognosis of patients with CLL may be predicted using a number of biomarkers, including the level of CD38 expression at the leukemic cell surface. This study investigates the hypothesis that CD38 expression by CLL cells reflects interactions with nonmalignant cells within pseudofollicles in secondary lymphoid tissue where tumor cell proliferation is thought to occur. CD38 expression is higher in tissues that contain pseudofollicles compared with those that do not. In addition, we show that CD38 expression in CLL is dynamic, changes in response to contact with activated CD4+ T cells, and identifies cells that are primed to proliferate. Finally, we demonstrate close contact between activated CD4+ T cells and proliferating tumor in primary patient tissue. Proliferating tumor cells in lymph nodes express CD38, which is in turn associated with an increased number of CD31+ vascular endothelial cells. Although the factors resulting in colocalization of tumor, T cells, and endothelium remain unclear, the existence of these cellular clusters may provide an explanation for the association between CD38 expression and adverse outcome in CLL and suggests novel therapeutic targets.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2007-08-108605

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 43

  1. Rai, 1975, Clinical staging of chronic lymphocytic leukemia., Blood, 46, 219, 10.1182/blood.V46.2.219.bloodjournal462219 · DOI
  2. Binet, 1981, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis., Cancer, 48, 198, 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V · DOI
  3. Damle, 1999, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia., Blood, 94, 1840, 10.1182/blood.V94.6.1840 · DOI
  4. Hamblin, 1999, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia., Blood, 94, 1848, 10.1182/blood.V94.6.1848 · DOI
  5. Ghia, 2003, The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression., Blood, 101, 1262, 10.1182/blood-2002-06-1801 · DOI
  6. Hamblin, 2002, CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease., Blood, 99, 1023, 10.1182/blood.V99.3.1023 · DOI
  7. Ibrahim, 2001, CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia., Blood, 98, 181, 10.1182/blood.V98.1.181 · DOI
  8. Krober, 2002, V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia., Blood, 100, 1410, 10.1182/blood.V100.4.1410.h81602001410_1410_1416 · DOI
  9. Matrai, 2001, CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia., Blood, 97, 1902, 10.1182/blood.V97.6.1902 · DOI
  10. Chang, 2002, Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course., Blood, 100, 1106, 10.1182/blood-2002-04-1287 · DOI
  11. Alessio, 1990, CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells., J Immunol, 145, 878, 10.4049/jimmunol.145.3.878 · DOI
  12. Deaglio, 2001, Human CD38: a (r)evolutionary story of enzymes and receptors., Leuk Res, 25, 1, 10.1016/S0145-2126(00)00093-X · DOI
  13. Morabito, 2006, The CD38 ectoenzyme family: advances in basic science and clinical practice., Mol Med, 12, 342, 10.2119/2006-00110.Morabito · DOI
  14. Kumagai, 1995, Ligation of CD38 suppresses human B lymphopoiesis., J Exp Med, 181, 1101, 10.1084/jem.181.3.1101 · DOI
  15. Zupo, 1994, CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells., Eur J Immunol, 24, 1218, 10.1002/eji.1830240532 · DOI
  16. Deaglio, 2005, CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival., Blood, 105, 3042, 10.1182/blood-2004-10-3873 · DOI
  17. Granziero, 2003, CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes., Blood, 101, 1962, 10.1182/blood-2002-05-1339 · DOI
  18. Pittner, 2005, CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation., Leukemia, 19, 2264, 10.1038/sj.leu.2403975 · DOI
  19. Swerdlow, 1984, Lymphocytic lymphoma/B-chronic lymphocytic leukaemia: an immunohistopathological study of peripheral B lymphocyte neoplasia., Br J Cancer, 50, 587, 10.1038/bjc.1984.225 · DOI
  20. Ben-Ezra, 1989, Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases., Blood, 73, 579, 10.1182/blood.V73.2.579.579 · DOI
  21. Schmid, 1994, Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study., Histopathology, 24, 445, 10.1111/j.1365-2559.1994.tb00553.x · DOI · Paper page
  22. Bonato, 1998, Lymph node histology in typical and atypical chronic lymphocytic leukemia., Am J Surg Pathol, 22, 49, 10.1097/00000478-199801000-00006 · DOI
  23. Lampert, 1999, High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen., Hum Pathol, 30, 648, 10.1016/S0046-8177(99)90089-8 · DOI
  24. Asplund, 2002, Immunophenotype does not correlate with lymph node histology in chronic lymphocytic leukemia/small lymphocytic lymphoma., Am J Surg Pathol, 26, 624, 10.1097/00000478-200205000-00008 · DOI
  25. Pizzolo, 1983, Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia., Blood, 62, 1289, 10.1182/blood.V62.6.1289.bloodjournal6261289 · DOI
  26. Granziero, 2001, Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia., Blood, 97, 2777, 10.1182/blood.V97.9.2777 · DOI
  27. Ghia, 2002, Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22., Eur J Immunol, 32, 1403, 10.1002/1521-4141(200205)32:5<1403::AID-IMMU1403>3.0.CO;2-Y · DOI
  28. Moreau, 1997, Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b)., Am J Clin Pathol, 108, 378, 10.1093/ajcp/108.4.378 · DOI
  29. Cook, 1995, The human immunoglobulin VH repertoire., Immunol Today, 16, 237, 10.1016/0167-5699(95)80166-9 · DOI
  30. Patten, 2005, Effect of CD3/CD28 bead-activated and expanded T cells on leukemic B cells in chronic lymphocytic leukemia [letter]., J Immunol, 174, 6562, 10.4049/jimmunol.174.11.6562 · DOI
  31. Cantwell, 1997, Acquired CD40-ligand deficiency in chronic lymphocytic leukemia., Nat Med, 3, 984, 10.1038/nm0997-984 · DOI
  32. Deaglio, 1998, Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member., J Immunol, 160, 395, 10.4049/jimmunol.160.1.395 · DOI
  33. Jaksic, 2004, CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow., Blood, 103, 1968, 10.1182/blood-2003-11-3890 · DOI
  34. Damle, 2007, CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells., Blood, 110, 3352, 10.1182/blood-2007-04-083832 · DOI
  35. Bennett, 2007, B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle., Br J Haematol, 139, 600, 10.1111/j.1365-2141.2007.06790.x · DOI
  36. Chiorazzi, 2003, B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor., Annu Rev Immunol, 21, 841, 10.1146/annurev.immunol.21.120601.141018 · DOI
  37. Ishida, 2006, Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege., Cancer Res, 66, 5716, 10.1158/0008-5472.CAN-06-0261 · DOI
  38. Lee, 2006, Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome., J Clin Oncol, 24, 5052, 10.1200/JCO.2006.06.4642 · DOI
  39. Till, 2005, CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium., Blood, 105, 4813, 10.1182/blood-2004-10-4054 · DOI
  40. Deaglio, 2007, CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential., Blood, 110, 4012, 10.1182/blood-2007-06-094029 · DOI
  41. Aguayo, 2000, Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia., Blood, 96, 768, 10.1182/blood.V96.2.768 · DOI
  42. Chen, 2000, In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells., Blood, 96, 3181, 10.1182/blood.V96.9.3181 · DOI
  43. McCabe, 2004, CD38 expression on B-cell chronic lymphocytic leukemic cells is strongly correlated with vascular endothelial growth factor expression., Leukemia, 18, 649, 10.1038/sj.leu.2403282 · DOI

Cited by

Metadata

Authors
Patten, P. E. M., Buggins, A. G. S., Richards, J., Wotherspoon, A., Salisbury, J., Mufti, G. J., Hamblin, T. J., & Devereux, S.
Affiliations
  • Department of Haematological and Molecular Medicine, King's College London, Rayne Institute, London;
  • Department of Histopathology, Royal Marsden Hospital, London; and
  • Department of Histopathology, King's College London, London, United Kingdom
Venue
Blood
Publisher
American Society of Hematology
Published
2008-05-15
Volume
111
Issue
10
Pages
5173-5181
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2007-08-108605
Cited by
196
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review